On Thursday, October 31, a Maryland federal judge denied a bid by Classen Immunotherapies, Inc. to reconsider a 2006 summary judgment granted to Elan Pharmaceuticals, Inc. over two patents related to muscle relaxant Skelaxin®. Finnegan represented Elan in this matter. James B. Monroe, Finnegan counsel to Elan, told Law360 “they are pleased with the result.”
